Volta Medical Gains Recognition in International Cardiac Electrophysiology Consensus

Volta Medical's advances in artificial intelligence (AI) solutions were acknowledged in a recent consensus statement from key international cardiac electrophysiology societies. The statement, which focuses on atrial fibrillation (AF) ablation advancements, was featured in the EP Europace Journal. It particularly highlights Volta Medical's AI companion software and its role in the TAILORED-AF clinical study designed to improve catheter and surgical treatments for AF.

According to the consensus, the TAILORED-AF clinical trial aims to test the effectiveness of a tailored AI software-guided ablation against a conventional anatomical ablation procedure, with results expected to be published soon. Dr. Jérôme Kalifa, Volta Medical Chief Medical Officer, expressed pride in the inclusion of their spatio-temporal dispersion-guided AI solutions and anticipated significant impacts on clinical practices. This endorsement by leading experts underlines Volta Medical's commitment to enhancing treatment options for AF with innovative technologies.

The 2024 consensus statement, backed by major cardiac electrophysiology associations such as the European Heart Rhythm Association and the Heart Rhythm Society, consolidated clinical advice based on extensive literature reviews and detailed surveys, requiring a minimum of 80% approval from voting participants.